Published in Cancer Treat Rep on November 01, 1984
Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study. Invest New Drugs (1999) 0.81
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54
Blood levels of organochlorine residues and risk of breast cancer. J Natl Cancer Inst (1993) 8.11
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Risk factors for Kaposi's sarcoma in homosexual men. Lancet (1982) 4.70
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS (1987) 3.78
Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water. Hypersensitivity pneumonitis or infection? Chest (1997) 3.69
Hog cholera virus: molecular composition of virions from a pestivirus. J Virol (1991) 3.24
Perioperative ischaemia in aortic surgery: combined epidural/general anaesthesia and epidural analgesia vs general anaesthesia and i.v. analgesia. Can J Anaesth (1996) 3.24
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
Pestivirus glycoprotein which induces neutralizing antibodies forms part of a disulfide-linked heterodimer. J Virol (1990) 2.75
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol (1995) 2.26
Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol (1989) 2.19
No evidence of acute cardiovascular complications of chemotherapy for testicular cancer: an analysis of the Testicular Cancer Intergroup Study. J Clin Oncol (1992) 2.11
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Rearrangement of viral sequences in cytopathogenic pestiviruses. Virology (1992) 1.98
Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest (2000) 1.94
Structural proteins of hog cholera virus expressed by vaccinia virus: further characterization and induction of protective immunity. J Virol (1991) 1.93
CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men. AIDS (1991) 1.85
Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol (1995) 1.77
Hog cholera virus--characterization of specific antiserum and identification of cDNA clones. Virology (1989) 1.75
Pleural mesothelioma: clinical features and therapeutic implications. Ann Intern Med (1977) 1.70
Risk of breast cancer and organochlorine exposure. Cancer Epidemiol Biomarkers Prev (2000) 1.70
Identification of a structural glycoprotein of an RNA virus as a ribonuclease. Science (1993) 1.67
Risk assessment for case-control subgroups by polychotomous logistic regression. Am J Epidemiol (1986) 1.66
Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol (2003) 1.63
Clinical studies with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (NSC 79037). Cancer Res (1971) 1.57
The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol (1989) 1.53
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol (2005) 1.50
Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med (1978) 1.48
Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Res (1983) 1.47
Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol (1991) 1.47
Treatment of breast cancer with medroxyprogesterone acetate. Ann Intern Med (1968) 1.45
Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res (1981) 1.45
Cytopathogenicity of a pestivirus correlates with a 27-nucleotide insertion. J Virol (1996) 1.44
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst (1996) 1.40
Cis-diamminedichloroplatinum (II). A new anticancer drug. Ann Intern Med (1977) 1.40
The insula is not specifically involved in disgust processing: an fMRI study. Neuroreport (2002) 1.38
A second envelope glycoprotein mediates neutralization of a pestivirus, hog cholera virus. J Virol (1992) 1.34
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep (1972) 1.32
Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst (1998) 1.32
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med (1987) 1.30
Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. J Virol (1995) 1.28
Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (1989) 1.25
N-terminal protease of pestiviruses: identification of putative catalytic residues by site-directed mutagenesis. J Virol (1998) 1.25
Heterosexual transmission of HIV in a cohort of couples in New York City. AIDS (1993) 1.23
Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst (1990) 1.22
Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther (1980) 1.21
Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res (1995) 1.20
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res (1980) 1.20
A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. I. Emergence and recovery profiles. Anesth Analg (2001) 1.19
Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med (1980) 1.19
Solubilization and molecular characterization of membrane-bound antigens shared by thymocytes and brain. Eur J Immunol (1976) 1.18
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med (1988) 1.18
Cytotoxic drug-induced pulmonary disease: update 1980. Am J Med (1980) 1.18
Bone-marrow examination in 100 consecutive patients with bronchogenic carcinoma. Lancet (1971) 1.18
Lung cancer: diagnosis in metastatic sites. Semin Oncol (1974) 1.17
Methodology for the assessment of new dichotomous diagnostic tests. J Chronic Dis (1981) 1.16
Antigenic correlations between brain and thymus. I. Common antigenic structures in rat and mouse brain tissue and thymocytes. Eur J Immunol (1972) 1.16
Regional lymph node dissection for malignant melanoma of the extremities. Surgery (1981) 1.16
Phase I study of (6R)-5,10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst (1993) 1.15
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res (1993) 1.15
Efficacy of 6-diazo-5-oxo-L-norleucine and N-[N-gamma-glutamyl-6-diazo-5-oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res (1979) 1.14
Modification of a commercial atomic force microscopy for low-noise, high-resolution frequency-modulation imaging in liquid environment. Rev Sci Instrum (2011) 1.14
RNase of classical swine fever virus: biochemical characterization and inhibition by virus-neutralizing monoclonal antibodies. J Virol (1996) 1.13
Camptothecins: a review of their development and schedules of administration. Eur J Cancer (1998) 1.12
Secondary ovarian carcinoma: a clinical and pathological evaluation. Int J Gynecol Pathol (1987) 1.12
Lysozymuria and renal tubular dysfunction in monocytic and myelomonocytic leukemia. Am J Med (1969) 1.11
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies. J Liposome Res (2003) 1.11
Estimation and sample size considerations for clustered binary responses. Stat Med (1994) 1.10
Hypercalcemia associated with neoplastic disease. Ann Intern Med (1970) 1.10
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med (1976) 1.10
Neural, electrodermal and behavioral response patterns in contingency aware and unaware subjects during a picture-picture conditioning paradigm. Neuroscience (2008) 1.09
Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res (1999) 1.09
Primary melanoma thickness correlated with regional lymph node metastases. Arch Surg (1982) 1.09
Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol (1989) 1.08
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis (1991) 1.08
Scalpel excision of basal cell carcinomas. Arch Dermatol (1978) 1.08
Role of chemotherapy in head and neck cancer: systemic use of single agents and combinations in advanced disease. Head Neck Surg (1980) 1.08
Challenges posed by non-random missing quality of life data in an advanced-stage colorectal cancer clinical trial. Psychooncology (2000) 1.08
Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res (1982) 1.08
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol (1992) 1.08
Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur J Cancer (1981) 1.07
Sex, drugs, and HIV infection in a New York City hospital outpatient population. J Acquir Immune Defic Syndr (1990) 1.06
Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. Hum Pathol (2001) 1.04
Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol (1984) 1.02
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02
Letter: Lack of antigenic correlations between brain and thymus. Lancet (1973) 1.02
Prognosis of patients with pathologic stage II cutaneous malignant melanoma. Ann Surg (1985) 1.02
Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome. Cancer (2001) 1.01
Pulmonary toxicity of antitumor agents. Cancer Treat Rev (1983) 1.00
Epidemiology of malignant melanoma: pigmentary traits, ultraviolet radiation, and the identification of high-risk populations. Recent Results Cancer Res (1986) 1.00